Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Amortizatization of Intangibles: 2011-2025

Historic Amortizatization of Intangibles for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $170,000.

  • Adma Biologics' Amortizatization of Intangibles fell 32.54% to $170,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $739,000, marking a year-over-year decrease of 48.32%. This contributed to the annual value of $951,000 for FY2024, which is 63.34% down from last year.
  • Per Adma Biologics' latest filing, its Amortizatization of Intangibles stood at $170,000 for Q3 2025, which was up 6.25% from $160,000 recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Amortizatization of Intangibles peaked at $981,066 during Q3 2022, and registered a low of $160,000 during Q2 2025.
  • In the last 3 years, Adma Biologics' Amortizatization of Intangibles had a median value of $252,000 in 2024 and averaged $369,545.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first surged by 101.87% in 2022, then plummeted by 68.62% in 2024.
  • Over the past 5 years, Adma Biologics' Amortizatization of Intangibles (Quarterly) stood at $502,858 in 2021, then dropped by 1.79% to $493,873 in 2022, then spiked by 41.33% to $698,000 in 2023, then plummeted by 68.62% to $219,000 in 2024, then slumped by 32.54% to $170,000 in 2025.
  • Its Amortizatization of Intangibles was $170,000 in Q3 2025, compared to $160,000 in Q2 2025 and $190,000 in Q1 2025.